dr. abou-alfa on the fda approval of cabozantinib in hcc
Published 5 years ago • 261 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
0:54
dr. singal on the fda approval of cabozantinib in hcc
-
1:08
dr. abou-alfa on sequencing agents in the treatment of patients with hcc
-
1:43
dr. ghassan abou-alfa on met inhibition with tivantinib and cabozantinib in liver cancer
-
1:36
dr. abou-alfa discusses new treatment options in hcc
-
2:04
dr. abou-alfa on key trends in hcc research
-
5:31
fda d.i.s.c.o.: fda approval of cabozantinib for hepatocellular carcinoma
-
1:21
dr. abou-alfa on sorafenib plus doxorubicin in patients with hcc
-
1:33
dr. abou-alfa on trials investigating immunotherapy in hcc
-
2:28
dr. abou-alfa discusses results of the celestial trial in advanced hcc
-
6:00
clinical rationale for cabozantinib in hcc
-
1:44
dr. abou-alfa on key eligibility criteria for the proof trial in cholangiocarcinoma
-
1:06
dr. choueiri on fda approval of cabozantinib for rcc
-
2:00
dr. abou-alfa on the results of the claridhy trial in advanced cholangiocarcinoma
-
1:09
dr. ghassan abou-alfa on the utility of doxorubicin-eluting beads in hepatocellular carcinoma
-
6:39
emerging second-line therapies in hcc
-
1:32
ghassan abou-alfa talks pemigatinib and cabozantinib
-
3:15
advances in systemic therapy for hcc
-
2:45
sequencing with cabozantinib in advanced hcc
-
1:40
dr. ghassan abou-alfa on doxorubicin plus sorafenib in liver cancer